November 1st, 2021 – GlycoCore Pharma S.r.l. is born

7 Jun , 2022

GlycoCore Pharma S.r.l. was incorporated on October 14th, 2021 as a spin-off of the innovative SME Jointherapeutics S.r.l., which was dedicated for years to research and development of technologies and polysaccharide products for the treatment of galectins-mediated inflammatory and fibrotic processes.

GlycoCore Pharma holds intellectual properties and know-hows especially developed for lung diseases. The Company aims to launch on the market a new molecule for the therapy of chronic and inflammatory diseases of the respiratory tract.

GlycoCore Pharma goal relies on relevant scientific findings, claiming the involvement of a class of lectins, galectins, in the inflammatory and fibrotic processes of various organs, including the lung. Furthermore, preliminary studies on HYLACH®, an innovative proprietary molecule, have highlighted its ability to interact with galectins, in particular galectin-3.

Several studies have correlated galectin-3 with the progression of various respiratory diseases such as, idiopathic pulmonary fibrosis (IPF), a progressive, and fibrotic lung disease; chronic obstructive pulmonary disease (COPD), a chronic lung disease where the inflammation process prevails; acute respiratory distress syndrome (ARDS) caused by a late-stage widespread infection.

HYLACH® employment for the treatment of IPF, COPD and ARDS relies on preclinical efficacy currently under investigation by several academic partners. These studies will elucidate HYLACH® performances in conjugating antifibrotic and antinflammatory properties, assessing the absence of cytotoxicity.

In an initial phase, preclinical activities, and resources fundamental for filing the Investigational Medicinal Product Dossier (IMPD) within 24 months and access clinical phase I, will be financially supported by private investors.

Financial resources to complete phase 1 and 2 clinical trials will be collected via a subsequent fundraising phase, expected by mid 2023.

Comments are closed.